| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-12-08 | monitoring biotherapies | rheumatoid arthritis | 4 | University Hospital, Strasbourg (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-12-08 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | acute lymphoblastic leukemia (ALL) | 2-3 | Erytech Pharma (France) | Cancer - Oncology |
| 2015-12-07 | AB103 | necrotizing soft tissue infections | 3 | Atox Bio (Israel) | Infectious diseases |
| 2015-12-07 | Prohema® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) | hematologic malignancies including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and non-Hodgkin lymphoma (NHL) | 2 | Fate Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-12-07 | masitinib | systemic severe mastocytosis | 3 | AB Science (France) | Rare diseases - Immunological diseases |
| 2015-12-07 | plasminogen | plasminogen deficiency | 1 | ProMetic Life Sciences (Canada) | Rare diseases |
| 2015-12-07 | venetoclax (RG7601, GDC-0199/ABT-199 | patients with previously treated (relapsed or refractory) chronic lymphocytic leukemia (CLL) harboring the 17p deletion |
2 | Genentech, a member of Roche Group (USA - CA - Switzerland) AbbVie (USA -IL) | Cancer - Oncology |
| 2015-12-07 | Adynovate® - BAX 855 | hemophilia A | 2-3 | Baxalta (USA - IL) | Rare diseases - Genetic diseases - Hematological diseases |
| 2015-12-07 | CD19-directed, CAR-modified T Cells | advanced CD19+ malignancies after hematopoietic stem-cell transplantation (HSCT) | Ziopharm Oncology (USA - MA) | Cancer - Oncology | |
| 2015-12-07 | IMMU-114 | non-hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma | 1 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2015-12-06 | AFM11 and AFM12 (T-cell and NK-cell TandAbs generated against EGFRvIII) | preclinical | Affimed (Germany) | Cancer - Oncology | |
| 2015-12-06 | AFM13 | preclinical | Affimed (Germany) | Cancer - Oncology | |
| 2015-12-06 | anti-BCMA CAR T cells | preclinical | Bluebird bio (USA - MA) | Cancer - Oncology | |
| 2015-12-06 | bb2121 anti-BCMA CAR T cells | preclinical | Bluebird bio (USA - MA) | Cancer - Oncology | |
| 2015-12-06 | belinostat | peripheral T-cell lymphoma | 1 | Topotarget (Denmark), now Onxeo (France) Spectrum Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-12-06 | AG-221 | advanced hematologic malignancies | 1 | Agios Pharmaceuticals (USA -MA) | Cancer - Oncology |
| 2015-12-06 | denintuzumab mafodotin (SGN-CD19A) | large B-cell lymphoma (DLBCL), B-lineage acute lymphocytic leukemia (B-ALL) | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology - Rare diseases |
| 2015-12-06 | SGN-CD19B | B cell malignancies | preclinical | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2015-12-05 | ADCT-402 | hematological cancers | preclinical | ADC Therapeutics (Switzerland) | Cancer - Oncology |
| 2015-12-05 | ADCT-301 | hematological cancers including lymphoma and leukemia | preclinical | ADC Therapeutics (Switzerland) | Cancer - Oncology |
